My watch list
my.chemeurope.com  
Login  

Terazosin



Terazosin
Systematic (IUPAC) name
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl) piperazin-1-yl]- tetrahydrofuran-2-yl-methanone
Identifiers
CAS number 63590-64-7
ATC code G04CA03
PubChem 5401
DrugBank APRD00667
Chemical data
Formula C19H25N5O4 
Mol. mass 387.433 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 90-94%
Metabolism  ?
Half life 12 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Terazosin (Hytrin®) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefor a drug of choice for men with hypertension and prostate enlargement.

Additional recommended knowledge

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon.[1] Sexual side effects are rare, but may include priapism or erectile dysfunction.


References

  1. ^ http://www.rxlist.com/cgi/generic/teraz_wcp.htm
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Terazosin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE